Expression of the familial hypercholesterolemia gene in heterozygotes: model for a dominant disorder in man

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Citations (Scopus)

Abstract

Little is known about the biochemical mechanisms by which dominant genes act. Nearly all of the hereditary metabolic disorders characterized at the molecular level have proved to be due to specific enzyme deficiencies inherited in a recessive pattern. In these recessive disorders the half normal enzyme activities that occur in heterozygotes are sufficient to prevent clinical disease. For dominant disorders, this type of metabolic reserve does not exist and heterozygotes are clinically affected. For this reason, McKusick has suggested that dominant mutations are likely to involve abnormalities not in enzymes, but in nonenzymic proteins such as those that are postulated to regulate complex metabolic pathways. Recently it has been shown that one dominant disorder, Familial Hypercholesterolemia, is due to a mutation involving a regulatory protein. An analysis of the expression of this regulatory defect in heterozygotes has provided new insight into one mechanism for dominant gene action in man.

Original languageEnglish (US)
Title of host publicationTransactions of the Association of American Physicians
Pages120-131
Number of pages12
Volume87
StatePublished - 1974

Fingerprint

Hyperlipoproteinemia Type II
Heterozygote
Dominant Genes
Enzymes
Genes
Mutation
Metabolic Networks and Pathways
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Expression of the familial hypercholesterolemia gene in heterozygotes : model for a dominant disorder in man. / Goldstein, J. L.; Brown, M. S.

Transactions of the Association of American Physicians. Vol. 87 1974. p. 120-131.

Research output: Chapter in Book/Report/Conference proceedingChapter

Goldstein, JL & Brown, MS 1974, Expression of the familial hypercholesterolemia gene in heterozygotes: model for a dominant disorder in man. in Transactions of the Association of American Physicians. vol. 87, pp. 120-131.
Goldstein JL, Brown MS. Expression of the familial hypercholesterolemia gene in heterozygotes: model for a dominant disorder in man. In Transactions of the Association of American Physicians. Vol. 87. 1974. p. 120-131
@inbook{ff170e9a463c4032b3d9ef5995520de2,
title = "Expression of the familial hypercholesterolemia gene in heterozygotes: model for a dominant disorder in man",
abstract = "Little is known about the biochemical mechanisms by which dominant genes act. Nearly all of the hereditary metabolic disorders characterized at the molecular level have proved to be due to specific enzyme deficiencies inherited in a recessive pattern. In these recessive disorders the half normal enzyme activities that occur in heterozygotes are sufficient to prevent clinical disease. For dominant disorders, this type of metabolic reserve does not exist and heterozygotes are clinically affected. For this reason, McKusick has suggested that dominant mutations are likely to involve abnormalities not in enzymes, but in nonenzymic proteins such as those that are postulated to regulate complex metabolic pathways. Recently it has been shown that one dominant disorder, Familial Hypercholesterolemia, is due to a mutation involving a regulatory protein. An analysis of the expression of this regulatory defect in heterozygotes has provided new insight into one mechanism for dominant gene action in man.",
author = "Goldstein, {J. L.} and Brown, {M. S.}",
year = "1974",
language = "English (US)",
volume = "87",
pages = "120--131",
booktitle = "Transactions of the Association of American Physicians",

}

TY - CHAP

T1 - Expression of the familial hypercholesterolemia gene in heterozygotes

T2 - model for a dominant disorder in man

AU - Goldstein, J. L.

AU - Brown, M. S.

PY - 1974

Y1 - 1974

N2 - Little is known about the biochemical mechanisms by which dominant genes act. Nearly all of the hereditary metabolic disorders characterized at the molecular level have proved to be due to specific enzyme deficiencies inherited in a recessive pattern. In these recessive disorders the half normal enzyme activities that occur in heterozygotes are sufficient to prevent clinical disease. For dominant disorders, this type of metabolic reserve does not exist and heterozygotes are clinically affected. For this reason, McKusick has suggested that dominant mutations are likely to involve abnormalities not in enzymes, but in nonenzymic proteins such as those that are postulated to regulate complex metabolic pathways. Recently it has been shown that one dominant disorder, Familial Hypercholesterolemia, is due to a mutation involving a regulatory protein. An analysis of the expression of this regulatory defect in heterozygotes has provided new insight into one mechanism for dominant gene action in man.

AB - Little is known about the biochemical mechanisms by which dominant genes act. Nearly all of the hereditary metabolic disorders characterized at the molecular level have proved to be due to specific enzyme deficiencies inherited in a recessive pattern. In these recessive disorders the half normal enzyme activities that occur in heterozygotes are sufficient to prevent clinical disease. For dominant disorders, this type of metabolic reserve does not exist and heterozygotes are clinically affected. For this reason, McKusick has suggested that dominant mutations are likely to involve abnormalities not in enzymes, but in nonenzymic proteins such as those that are postulated to regulate complex metabolic pathways. Recently it has been shown that one dominant disorder, Familial Hypercholesterolemia, is due to a mutation involving a regulatory protein. An analysis of the expression of this regulatory defect in heterozygotes has provided new insight into one mechanism for dominant gene action in man.

UR - http://www.scopus.com/inward/record.url?scp=0016233680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016233680&partnerID=8YFLogxK

M3 - Chapter

C2 - 4376290

AN - SCOPUS:0016233680

VL - 87

SP - 120

EP - 131

BT - Transactions of the Association of American Physicians

ER -